Start the conversation
Today marks exactly two months since we recommended Emergent BioSolutions Inc. (NYSE: EBS) - which we pitched as an "immunotherapy stock with a twist."
In that short stretch, Emergent is up 25.5%. That's an annualized return of 153%.
And there's more to come...
This is premium content for Private Briefing subscribers only.